{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:55:19Z","timestamp":1785772519206,"version":"3.56.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100013238","name":"Faculty of Medicine Siriraj Hospital, Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"DOI":"10.1007\/s12072-026-11135-y","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:16:49Z","timestamp":1785770209000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["National guideline for hepatitis B elimination in Thailand: a decentralized health system model for expanding diagnosis and treatment"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8334-0267","authenticated-orcid":false,"given":"Phunchai","family":"Charatcharoenwitthaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawesak","family":"Tanwandee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pisit","family":"Tangkijvanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teerha","family":"Piratvisuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chatree","family":"Jullapetch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheewanan","family":"Lertpiriyasuwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pongtorn","family":"Chartpitak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"3","key":"11135_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"11135_CR2","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2020","unstructured":"Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2020;77(6):1598\u20131606. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.021","journal-title":"J Hepatol"},{"issue":"4","key":"11135_CR3","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","volume":"62","author":"GV Papatheodoridis","year":"2015","unstructured":"Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62(4):956\u2013967. https:\/\/doi.org\/10.1016\/j.jhep.2015.01.002","journal-title":"J Hepatol"},{"issue":"1","key":"11135_CR4","first-page":"1","volume":"43","author":"Y Poovorawan","year":"2025","unstructured":"Poovorawan Y, Inma P, Nilyanimit P, Kanokudom S, Jullapetch C. Lessons from Thailand\u2019s successful prevention of mother-to-child hepatitis B transmission: advancing toward elimination by 2030. Asian Pac J Allergy Immunol. 2025;43(1):1\u20139","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"3","key":"11135_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150499","volume":"11","author":"N Posuwan","year":"2016","unstructured":"Posuwan N, Wanlapakorn N, Sa-Nguanmoo P, Wasitthankasem R, Vichaiwattana P, Klinfueng S, et al. The success of a universal Hepatitis B immunization program as part of Thailand\u2019s EPI after 22 years\u2019 implementation. PLoS ONE. 2016;11(3): e0150499. https:\/\/doi.org\/10.1371\/journal.pone.0150499","journal-title":"PLoS ONE"},{"issue":"1","key":"11135_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-84854-7","volume":"15","author":"P Nilyanimit","year":"2025","unstructured":"Nilyanimit P, Wanlapakorn N, Vichaiwattana P, Wongsrisang L, Klinfueng S, Suntronwong N, et al. Significant reduction in Hepatitis B virus infections following 32 years of universal Hepatitis B vaccination as part of EPI, Thailand. Sci Rep. 2025;15(1): 1167. https:\/\/doi.org\/10.1038\/s41598-024-84854-7","journal-title":"Sci Rep"},{"key":"11135_CR7","unstructured":"Organization WH. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. 2024, https:\/\/www.who.int\/publications\/i\/item\/9789240090903"},{"issue":"4","key":"11135_CR8","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1097\/HEP.0000000000001549","volume":"83","author":"MG Ghany","year":"2026","unstructured":"Ghany MG, Pan CQ, Lok AS, Feld JJ, Lim JK, Wang SH, et al. AASLD ISDA Practice Guideline on treatment of chronic hepatitis B. Hepatology. 2026;83(4):974\u2013997. https:\/\/doi.org\/10.1097\/HEP.0000000000001549","journal-title":"Hepatology"},{"issue":"2","key":"11135_CR9","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","volume":"83","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502\u2013583. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.018","journal-title":"J Hepatol"},{"key":"11135_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-026-11108-1","author":"H You","year":"2026","unstructured":"You H, Maiwall R, Chen J, Ahn SH, Dokmeci K, Dou X, et al. APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update. Hepatol Int. 2026. https:\/\/doi.org\/10.1007\/s12072-026-11108-1","journal-title":"Hepatol Int"},{"issue":"7","key":"11135_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067275","volume":"13","author":"C Janekrongtham","year":"2023","unstructured":"Janekrongtham C, Punsuwan N, Thitichai P, Lertpiriyasuwat C, Pan-Ngum W, Poovorawan K, et al. Cost-effectiveness of tenofovir prophylaxis during pregnancy for the elimination of mother-to-child transmission of the hepatitis B virus: real-world analysis from Thailand. BMJ Open. 2023;13(7): e067275. https:\/\/doi.org\/10.1136\/bmjopen-2022-067275","journal-title":"BMJ Open"},{"issue":"3","key":"11135_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jve.2020.100003","volume":"6","author":"N Posuwan","year":"2020","unstructured":"Posuwan N, Wanlapakorn N, Sintusek P, Wasitthankasem R, Poovorawan K, Vongpunsawad S, et al. Towards the elimination of viral hepatitis in Thailand by the year 2030. J Virus Erad. 2020;6(3): 100003. https:\/\/doi.org\/10.1016\/j.jve.2020.100003","journal-title":"J Virus Erad"},{"issue":"8","key":"11135_CR13","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.socscimed.2007.05.054","volume":"65","author":"SL Munira","year":"2007","unstructured":"Munira SL, Fritzen SA. What influences government adoption of vaccines in developing countries? A policy process analysis. Soc Sci Med. 2007;65(8):1751\u20131764. https:\/\/doi.org\/10.1016\/j.socscimed.2007.05.054","journal-title":"Soc Sci Med"},{"issue":"6","key":"11135_CR14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2471\/BLT.18.223693","volume":"97","author":"K Sumriddetchkajorn","year":"2019","unstructured":"Sumriddetchkajorn K, Shimazaki K, Ono T, Kusaba T, Sato K, Kobayashi N. Universal health coverage and primary care, Thailand. Bull World Health Organ. 2019;97(6):415\u2013422. https:\/\/doi.org\/10.2471\/BLT.18.223693","journal-title":"Bull World Health Organ"},{"key":"11135_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2024.101011","volume":"43","author":"P Dilokthornsakul","year":"2024","unstructured":"Dilokthornsakul P, Sawangjit R, Tangkijvanich P, Chayanupatkul M, Permsuwan U. Simplified chronic hepatitis B antiviral initiation criteria in Thailand: an economic evaluation. Value Health Reg Issues. 2024;43: 101011. https:\/\/doi.org\/10.1016\/j.vhri.2024.101011","journal-title":"Value Health Reg Issues"},{"issue":"4","key":"11135_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40258-022-00719-y","volume":"20","author":"P Dilokthornsakul","year":"2022","unstructured":"Dilokthornsakul P, Sawangjit R, Tangkijvanich P, Chayanupatkul M, Tanwandee T, Sukeepaisarnjaroen W, et al. Economic evaluation of oral nucleos(t)ide analogues for patients with chronic hepatitis B in Thailand. Appl Health Econ Health Policy. 2022;20(4):587\u2013596. https:\/\/doi.org\/10.1007\/s40258-022-00719-y","journal-title":"Appl Health Econ Health Policy"},{"issue":"9","key":"11135_CR17","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41575-020-0332-6","volume":"17","author":"AL Cox","year":"2020","unstructured":"Cox AL, El-Sayed MH, Kao JH, Lazarus JV, Lemoine M, Lok AS, et al. Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol. 2020;17(9):533\u2013542. https:\/\/doi.org\/10.1038\/s41575-020-0332-6","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"11135_CR18","unstructured":"Vimolket T, Poovorawan Y. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness. Southeast Asian J Trop Med Public Health 2005; 36(3):693\u2013699, https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16124440"},{"key":"11135_CR19","doi-asserted-by":"publisher","unstructured":"WHO. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. World Health Organization, Geneva. 2024:https:\/\/www.who.int\/publications\/i\/item\/9789240090903 (accessed date: 27 Mar 2026). https:\/\/doi.org\/10.1097\/ID9.0000000000000128","DOI":"10.1097\/ID9.0000000000000128"},{"issue":"10","key":"11135_CR20","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S2468-1253(21)00267-3","volume":"6","author":"P Easterbrook","year":"2021","unstructured":"Easterbrook P, Luhmann N, Newman M, Walsh N, Lesi O, Doherty M. New WHO guidance for country validation of viral hepatitis B and C elimination. Lancet Gastroenterol Hepatol. 2021;6(10):778\u2013780. https:\/\/doi.org\/10.1016\/S2468-1253(21)00267-3","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"11135_CR21","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/j.1537-2995.2010.03023.x","volume":"51","author":"S Louisirirotchanakul","year":"2011","unstructured":"Louisirirotchanakul S, Oota S, Khuponsarb K, Chalermchan W, Phikulsod S, Chongkolwatana V, et al. Occult hepatitis B virus infection in Thai blood donors. Transfusion. 2011;51(7):1532\u20131540. https:\/\/doi.org\/10.1111\/j.1537-2995.2010.03023.x","journal-title":"Transfusion"},{"key":"11135_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102818","volume":"76","author":"TV Kim","year":"2024","unstructured":"Kim TV, Pham TND, Phan P, Le MHN, Le Q, Nguyen PT, et al. Effectiveness and implementation of decentralized, community- and primary care-based strategies in promoting hepatitis B testing uptake: a systematic review and meta-analysis. EClinicalMedicine. 2024;76: 102818. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102818","journal-title":"EClinicalMedicine"},{"issue":"5","key":"11135_CR23","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s10900-021-00977-2","volume":"46","author":"V Thaineua","year":"2021","unstructured":"Thaineua V, Karnkavinpong O, Traisathit P, Lertkietidamrong S, Maiton S, Nanthaprut P, et al. A proactive policy to eliminate viral hepatitis infection: five-year results for the Subdistrict Model in Thailand. J Community Health. 2021;46(5):927\u2013931. https:\/\/doi.org\/10.1007\/s10900-021-00977-2","journal-title":"J Community Health"},{"issue":"4","key":"11135_CR24","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S2468-1253(24)00437-0","volume":"10","author":"A Liguori","year":"2025","unstructured":"Liguori A, Zoncape M, Casazza G, Easterbrook P, Tsochatzis EA. Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025;10(4):332\u2013349. https:\/\/doi.org\/10.1016\/S2468-1253(24)00437-0","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"11135_CR25","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/apt.12307","volume":"37","author":"V de Ledinghen","year":"2013","unstructured":"de Ledinghen V, Vergniol J, Barthe C, Foucher J, Chermak F, Le Bail B, et al. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus. Aliment Pharmacol Ther. 2013;37(10):979\u2013988. https:\/\/doi.org\/10.1111\/apt.12307","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"11135_CR26","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/apt.14619","volume":"47","author":"TC Tseng","year":"2075","unstructured":"Tseng TC, Liu CJ, Su TH, Yang WT, Chen CL, Yang HC, et al. Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection. Aliment Pharmacol Ther. 2075;47(11):1480\u20131489. https:\/\/doi.org\/10.1111\/apt.14619","journal-title":"Aliment Pharmacol Ther"},{"issue":"28","key":"11135_CR27","doi-asserted-by":"publisher","first-page":"45768","DOI":"10.18632\/oncotarget.17470","volume":"8","author":"Q Li","year":"2017","unstructured":"Li Q, Lu C, Li W, Huang Y, Chen L. Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B. Oncotarget. 2017;8(28):45768\u201345776. https:\/\/doi.org\/10.18632\/oncotarget.17470","journal-title":"Oncotarget"},{"issue":"4","key":"11135_CR28","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/liv.13271","volume":"37","author":"P Charatcharoenwitthaya","year":"2017","unstructured":"Charatcharoenwitthaya P, Pongpaibul A, Kaosombatwattana U, Bhanthumkomol P, Bandidniyamanon W, Pausawasdi N, et al. The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response. Liver Int. 2017;37(4):542\u2013551. https:\/\/doi.org\/10.1111\/liv.13271","journal-title":"Liver Int"},{"issue":"2","key":"11135_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.cld.2026.01.013","volume":"30","author":"G Papatheodoridis","year":"2026","unstructured":"Papatheodoridis G, Lekakis V, Esteban R, Buti M. Metabolic dysfunction-associated steatotic liver disease and viral hepatitis. Clin Liver Dis. 2026;30(2):557\u2013569. https:\/\/doi.org\/10.1016\/j.cld.2026.01.013","journal-title":"Clin Liver Dis"},{"issue":"1","key":"11135_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.14218\/JCTH.2022.00055","volume":"11","author":"M Rugivarodom","year":"2023","unstructured":"Rugivarodom M, Pongpaibul A, Chainuvati S, Nimanong S, Chotiyaputta W, Tanwandee T, et al. Prognostic relevance of metabolic dysfunction-associated steatohepatitis for patients with chronic hepatitis B. J Clin Transl Hepatol. 2023;11(1):76\u201387. https:\/\/doi.org\/10.14218\/JCTH.2022.00055","journal-title":"J Clin Transl Hepatol"},{"key":"11135_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/v15030724","author":"T Geeratragool","year":"2023","unstructured":"Geeratragool T, Tangkijvanich P, Nimanong S, Chainuvati S, Charatcharoenwitthaya P, Tanwandee T, et al. A novel and simplified score for determining treatment eligibility for patients with chronic hepatitis B. Viruses. 2023. https:\/\/doi.org\/10.3390\/v15030724","journal-title":"Viruses"},{"issue":"2","key":"11135_CR32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S2468-1253(20)30307-1","volume":"6","author":"M Tan","year":"2021","unstructured":"Tan M, Bhadoria AS, Cui F, Tan A, Van Holten J, Easterbrook P, et al. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(2):106\u2013119. https:\/\/doi.org\/10.1016\/S2468-1253(20)30307-1","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"11135_CR33","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/gutjnl-2018-317593","volume":"69","author":"R Loomba","year":"2020","unstructured":"Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut. 2020;69(7):1343\u20131352. https:\/\/doi.org\/10.1136\/gutjnl-2018-317593","journal-title":"Gut"},{"key":"11135_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/v16101531","author":"S Sinclair 3rd","year":"2024","unstructured":"Sinclair S 3rd, Shearen S, Ghobrial Y, Trad G, Abdul Basit S, Shih D, et al. Review of the effects of antiviral therapy on hepatitis B\/C-related mortality and the regression of fibrosis. Viruses. 2024. https:\/\/doi.org\/10.3390\/v16101531","journal-title":"Viruses"},{"issue":"1","key":"11135_CR35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65\u201373. https:\/\/doi.org\/10.1001\/jama.295.1.65","journal-title":"JAMA"},{"issue":"3","key":"11135_CR36","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","volume":"130","author":"UH Iloeje","year":"2006","unstructured":"Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678\u2013686. https:\/\/doi.org\/10.1053\/j.gastro.2005.11.016","journal-title":"Gastroenterology"},{"issue":"2","key":"11135_CR37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/s-0032-1316476","volume":"32","author":"P Easterbrook","year":"2012","unstructured":"Easterbrook P, Sands A, Harmanci H. Challenges and priorities in the management of HIV\/HBV and HIV\/HCV coinfection in resource-limited settings. Semin Liver Dis. 2012;32(2):147\u2013157. https:\/\/doi.org\/10.1055\/s-0032-1316476","journal-title":"Semin Liver Dis"},{"key":"11135_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12121957","author":"JH Oh","year":"2022","unstructured":"Oh JH, Park DA, Ko MJ, Yoo JJ, Yim SY, Ahn JH, et al. Direct-acting antivirals and the risk of hepatitis B reactivation in hepatitis B and C co-infected patients: a systematic review and meta-analysis. J Pers Med. 2022. https:\/\/doi.org\/10.3390\/jpm12121957","journal-title":"J Pers Med"},{"issue":"1","key":"11135_CR39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13643-019-1126-1","volume":"8","author":"WWL Wong","year":"2019","unstructured":"Wong WWL, Pechivanoglou P, Wong J, Bielecki JM, Haines A, Erman A, et al. Antiviral treatment for treatment-naive chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Syst Rev. 2019;8(1):207. https:\/\/doi.org\/10.1186\/s13643-019-1126-1","journal-title":"Syst Rev"},{"issue":"5","key":"11135_CR40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","volume":"5","author":"P Lampertico","year":"2020","unstructured":"Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol. 2020;5(5):441\u2013453. https:\/\/doi.org\/10.1016\/S2468-1253(19)30421-2","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"11135_CR41","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/apt.70327","volume":"63","author":"GL Wong","year":"2026","unstructured":"Wong GL, Gane E, Pan CQ, Fung S, Ma MM, Izumi N, et al. Efficacy and safety of tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) followed by TAF in chronic hepatitis B patients of East Asian ethnicity following 5 years of treatment. Aliment Pharmacol Ther. 2026;63(1):132\u2013144. https:\/\/doi.org\/10.1111\/apt.70327","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"11135_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-03027-4","volume":"23","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhao Z, Ma X, Liu S, Xin Y. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with hepatitis B: a network meta-analysis. BMC Gastroenterol. 2023;23(1): 384. https:\/\/doi.org\/10.1186\/s12876-023-03027-4","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"11135_CR43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196\u2013206. https:\/\/doi.org\/10.1016\/S2468-1253(16)30107-8","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11-12","key":"11135_CR44","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/apt.18278","volume":"60","author":"M Buti","year":"2024","unstructured":"Buti M, Lim YS, Chan HLY, Agarwal K, Marcellin P, Brunetto MR, et al. Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: final results from two randomised phase 3 trials. Aliment Pharmacol Ther. 2024;60(11\u201312):1573\u20131586. https:\/\/doi.org\/10.1111\/apt.18278","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"11135_CR45","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HL Chan","year":"2016","unstructured":"Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185\u2013195. https:\/\/doi.org\/10.1016\/S2468-1253(16)30024-3","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"11135_CR46","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1128\/AAC.02483-13","volume":"58","author":"JH Lee","year":"2014","unstructured":"Lee JH, Cho Y, Lee DH, Lee M, Yoo JJ, Choi WM, et al. Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B patients without detectable lamivudine resistance. Antimicrob Agents Chemother. 2014;58(3):1730\u20131737. https:\/\/doi.org\/10.1128\/AAC.02483-13","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"11135_CR47","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3350\/cmh.2015.21.2.131","volume":"21","author":"JA Hwang","year":"2015","unstructured":"Hwang JA, Kim KB, Yang MJ, Lim SG, Hwang JC, Cheong JY, et al. Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients. Clin Mol Hepatol. 2015;21(2):131\u2013140. https:\/\/doi.org\/10.3350\/cmh.2015.21.2.131","journal-title":"Clin Mol Hepatol"},{"issue":"10","key":"11135_CR48","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/jmv.23363","volume":"84","author":"S Louisirirotchanakul","year":"2012","unstructured":"Louisirirotchanakul S, Olinger CM, Arunkaewchaemsri P, Poovorawan Y, Kanoksinsombat C, Thongme C, et al. The distribution of hepatitis B virus genotypes in Thailand. J Med Virol. 2012;84(10):1541\u20131547. https:\/\/doi.org\/10.1002\/jmv.23363","journal-title":"J Med Virol"},{"issue":"3","key":"11135_CR49","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jiph.2023.12.020","volume":"17","author":"S Sirilert","year":"2024","unstructured":"Sirilert S, Khamrin P, Kumthip K, Malasao R, Tongsong T, Maneekarn N. Hepatitis B virus genotypes associated with pregnant women in Northern Thailand. J Infect Public Health. 2024;17(3):406\u2013411. https:\/\/doi.org\/10.1016\/j.jiph.2023.12.020","journal-title":"J Infect Public Health"},{"issue":"4","key":"11135_CR50","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/jmv.24368","volume":"88","author":"P Yimnoi","year":"2016","unstructured":"Yimnoi P, Posuwan N, Wanlapakorn N, Tangkijvanich P, Theamboonlers A, Vongpunsawad S, et al. A molecular epidemiological study of the hepatitis B virus in Thailand after 22 years of universal immunization. J Med Virol. 2016;88(4):664\u2013673. https:\/\/doi.org\/10.1002\/jmv.24368","journal-title":"J Med Virol"},{"issue":"4","key":"11135_CR51","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/vox.12178","volume":"107","author":"N Chamni","year":"2014","unstructured":"Chamni N, Louisirirotchanakul S, Oota S, Sakuldamrongpanish T, Saldanha J, Chongkolwatana V, et al. Genetic characterization and genotyping of hepatitis B virus (HBV) isolates from donors with an occult HBV infection. Vox Sang. 2014;107(4):324\u2013332. https:\/\/doi.org\/10.1111\/vox.12178","journal-title":"Vox Sang"},{"issue":"3","key":"11135_CR52","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jhep.2005.03.018","volume":"43","author":"CM Chu","year":"2005","unstructured":"Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol. 2005;43(3):411\u2013417. https:\/\/doi.org\/10.1016\/j.jhep.2005.03.018","journal-title":"J Hepatol"},{"issue":"15","key":"11135_CR53","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.3748\/wjg.v11.i15.2238","volume":"11","author":"P Tangkijvanich","year":"2005","unstructured":"Tangkijvanich P, Mahachai V, Komolmit P, Fongsarun J, Theamboonlers A, Poovorawan Y. Hepatitis B virus genotypes and hepatocellular carcinoma in Thailand. World J Gastroenterol. 2005;11(15):2238\u20132243. https:\/\/doi.org\/10.3748\/wjg.v11.i15.2238","journal-title":"World J Gastroenterol"},{"issue":"16","key":"11135_CR54","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/jnci\/djn243","volume":"100","author":"HI Yang","year":"2008","unstructured":"Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(16):1134\u20131143. https:\/\/doi.org\/10.1093\/jnci\/djn243","journal-title":"J Natl Cancer Inst"},{"key":"11135_CR55","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/HMER.S291976","volume":"14","author":"T Broquetas","year":"2022","unstructured":"Broquetas T, Carrion JA. Current perspectives on nucleos(t)ide analogue therapy for the long-term treatment of hepatitis B virus. Hepat Med. 2022;14:87\u2013100. https:\/\/doi.org\/10.2147\/HMER.S291976","journal-title":"Hepat Med"},{"issue":"11","key":"11135_CR56","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/hiv.13542","volume":"24","author":"J Ambrosioni","year":"2023","unstructured":"Ambrosioni J, Levi L, Alagaratnam J, Van Bremen K, Mastrangelo A, Waalewijn H, et al. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Med. 2023;24(11):1126\u20131136. https:\/\/doi.org\/10.1111\/hiv.13542","journal-title":"HIV Med"},{"issue":"3","key":"11135_CR57","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","volume":"3","author":"MM Mucke","year":"2018","unstructured":"Mucke MM, Backus LI, Mucke VT, Coppola N, Preda CM, Yeh ML, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(3):172\u2013180. https:\/\/doi.org\/10.1016\/S2468-1253(18)30002-5","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"11135_CR58","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1055\/a-1630-7893","volume":"85","author":"J Harlfinger","year":"2023","unstructured":"Harlfinger J, Nussbaumer-Streit B, Gartlehner G. Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy. Gesundheitswesen. 2023;85(4):266\u2013269. https:\/\/doi.org\/10.1055\/a-1630-7893","journal-title":"Gesundheitswesen"},{"key":"11135_CR59","volume-title":"Prevention of Mother-to-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy","author":"WHO","year":"2022","unstructured":"WHO. Prevention of Mother-to-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy. Geneva: World Health Organization; 2022"},{"issue":"1","key":"11135_CR60","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S1473-3099(20)30586-7","volume":"21","author":"AL Funk","year":"2021","unstructured":"Funk AL, Lu Y, Yoshida K, Zhao T, Boucheron P, van Holten J, et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis. 2021;21(1):70\u201384. https:\/\/doi.org\/10.1016\/S1473-3099(20)30586-7","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"11135_CR61","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa1708131","volume":"378","author":"G Jourdain","year":"2018","unstructured":"Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med. 2018;378(10):911\u2013923. https:\/\/doi.org\/10.1056\/NEJMoa1708131","journal-title":"N Engl J Med"},{"issue":"24","key":"11135_CR62","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","volume":"374","author":"CQ Pan","year":"2016","unstructured":"Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324\u20132334. https:\/\/doi.org\/10.1056\/NEJMoa1508660","journal-title":"N Engl J Med"},{"issue":"1","key":"11135_CR63","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12876-018-0847-2","volume":"18","author":"W Li","year":"2018","unstructured":"Li W, Jia L, Zhao X, Wu X, Tang H. Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries. BMC Gastroenterol. 2018;18(1):121. https:\/\/doi.org\/10.1186\/s12876-018-0847-2","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"11135_CR64","doi-asserted-by":"publisher","first-page":"e3324","DOI":"10.1093\/cid\/ciaa1939","volume":"73","author":"QL Zeng","year":"2021","unstructured":"Zeng QL, Yu ZJ, Ji F, Li GM, Zhang GF, Xu JH, et al. Tenofovir alafenamide to prevent perinatal hepatitis B transmission: a multicenter, prospective, observational study. Clin Infect Dis. 2021;73(9):e3324\u2013e3332. https:\/\/doi.org\/10.1093\/cid\/ciaa1939","journal-title":"Clin Infect Dis"},{"issue":"26","key":"11135_CR65","doi-asserted-by":"publisher","first-page":"10551","DOI":"10.1080\/14767058.2022.2134771","volume":"35","author":"G Han","year":"2022","unstructured":"Han G, Zhou G, Sun T, Luo X, Xu J, Chen C, et al. Tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus: a multi-center, prospective study. J Matern Fetal Neonatal Med. 2022;35(26):10551\u201310558. https:\/\/doi.org\/10.1080\/14767058.2022.2134771","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"8","key":"11135_CR66","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1111\/liv.15249","volume":"42","author":"G Samadi Kochaksaraei","year":"2022","unstructured":"Samadi Kochaksaraei G, Shaheen AA, Seow CH, Barkema HW, Coffin CS. Tenofovir disoproxil fumarate therapy to prevent hepatitis B virus vertical transmission-A review of maternal and infant outcomes. Liver Int. 2022;42(8):1712\u20131730. https:\/\/doi.org\/10.1111\/liv.15249","journal-title":"Liver Int"},{"key":"11135_CR67","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2147\/IDR.S171695","volume":"12","author":"G Jourdain","year":"2019","unstructured":"Jourdain G, Ngo-Giang-Huong N, Khamduang W. Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications. Infect Drug Resist. 2019;12:977\u2013987. https:\/\/doi.org\/10.2147\/IDR.S171695","journal-title":"Infect Drug Resist"},{"issue":"4","key":"11135_CR68","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/cid\/ciae288","volume":"79","author":"CQ Pan","year":"2024","unstructured":"Pan CQ, Zhu L, Yu AS, Zhao Y, Zhu B, Dai E. Tenofovir alafenamide versus tenofovir disoproxil fumarate for preventing vertical transmission in chronic hepatitis B mothers: a systematic review and meta-analysis. Clin Infect Dis. 2024;79(4):953\u2013964. https:\/\/doi.org\/10.1093\/cid\/ciae288","journal-title":"Clin Infect Dis"},{"issue":"2","key":"11135_CR69","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40273-019-00852-y","volume":"38","author":"F Tian","year":"2020","unstructured":"Tian F, Houle SKD, Alsabbagh MW, Wong WWL. Cost-effectiveness of tenofovir alafenamide for treatment of chronic hepatitis B in Canada. Pharmacoeconomics. 2020;38(2):181\u2013192. https:\/\/doi.org\/10.1007\/s40273-019-00852-y","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"11135_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0327298","volume":"20","author":"Y Lin","year":"2025","unstructured":"Lin Y, Lin X, Xia R, Chen J, Lin Z, Lu S. Tenofovir alafenamide is superior to tenofovir disoproxil fumarate and entecavir in cost-effectiveness of treatment of chronic hepatitis B in China with new volume-based procurement policy. PLoS ONE. 2025;20(7): e0327298. https:\/\/doi.org\/10.1371\/journal.pone.0327298","journal-title":"PLoS ONE"},{"issue":"1","key":"11135_CR71","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jhep.2021.08.019","volume":"76","author":"Q Ye","year":"2022","unstructured":"Ye Q, Kam LY, Yeo YH, Dang N, Huang DQ, Cheung R, et al. Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. J Hepatol. 2022;76(1):63\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2021.08.019","journal-title":"J Hepatol"},{"issue":"4","key":"11135_CR72","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3350\/cmh.2022.0420","volume":"29","author":"YC Hsu","year":"2023","unstructured":"Hsu YC, Tseng CH, Kao JH. Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: first, do no harm. Clin Mol Hepatol. 2023;29(4):869\u2013890. https:\/\/doi.org\/10.3350\/cmh.2022.0420","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"11135_CR73","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/cld.140","volume":"2","author":"RP Perrillo","year":"2013","unstructured":"Perrillo RP. Hepatitis B virus treatment: which patients require immediate treatment. Clin Liver Dis (Hoboken). 2013;2(1):11\u201314. https:\/\/doi.org\/10.1002\/cld.140","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"4","key":"11135_CR74","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/j.1440-1746.2011.06695.x","volume":"26","author":"CJ Chen","year":"2011","unstructured":"Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol. 2011;26(4):628\u2013638. https:\/\/doi.org\/10.1111\/j.1440-1746.2011.06695.x","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"11135_CR75","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1053\/j.gastro.2010.01.042","volume":"138","author":"JD Chen","year":"2010","unstructured":"Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology. 2010;138(5):1747\u20131754. https:\/\/doi.org\/10.1053\/j.gastro.2010.01.042","journal-title":"Gastroenterology"},{"issue":"12","key":"11135_CR76","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.cgh.2013.04.043","volume":"11","author":"R Loomba","year":"2013","unstructured":"Loomba R, Liu J, Yang HI, Lee MH, Lu SN, Wang LY, et al. Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11(12):1636\u201345 e1-3. https:\/\/doi.org\/10.1016\/j.cgh.2013.04.043","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"11135_CR77","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317\u2013370. https:\/\/doi.org\/10.1007\/s12072-017-9799-9","journal-title":"Hepatol Int"},{"issue":"6","key":"11135_CR78","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922\u20131965. https:\/\/doi.org\/10.1097\/HEP.0000000000000466","journal-title":"Hepatology"},{"issue":"2","key":"11135_CR79","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jhep.2010.03.010","volume":"53","author":"V Santi","year":"2010","unstructured":"Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53(2):291\u2013297. https:\/\/doi.org\/10.1016\/j.jhep.2010.03.010","journal-title":"J Hepatol"},{"issue":"7","key":"11135_CR80","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","volume":"130","author":"BH Zhang","year":"2004","unstructured":"Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130(7):417\u2013422. https:\/\/doi.org\/10.1007\/s00432-004-0552-0","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"11135_CR81","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","volume":"154","author":"K Tzartzeva","year":"2018","unstructured":"Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706\u201318 e1. https:\/\/doi.org\/10.1053\/j.gastro.2018.01.064","journal-title":"Gastroenterology"},{"issue":"10","key":"11135_CR82","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.14309\/ajg.0000000000000715","volume":"115","author":"ND Parikh","year":"2020","unstructured":"Parikh ND, Singal AG, Hutton DW, Tapper EB. Cost-effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms. Am J Gastroenterol. 2020;115(10):1642\u20131649. https:\/\/doi.org\/10.14309\/ajg.0000000000000715","journal-title":"Am J Gastroenterol"},{"key":"11135_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16142521","author":"P Pastras","year":"2024","unstructured":"Pastras P, Zazas E, Kalafateli M, Aggeletopoulou I, Tsounis EP, Kanaloupitis S, et al. Predictive risk factors and scoring systems associated with the development of hepatocellular carcinoma in chronic hepatitis B. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16142521","journal-title":"Cancers (Basel)"},{"issue":"1","key":"11135_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-021-06794-6","volume":"21","author":"MF Sprinzl","year":"2021","unstructured":"Sprinzl MF, Feist C, Koch S, Kremer WM, Lackner KJ, Weinmann A, et al. Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B. BMC Health Serv Res. 2021;21(1): 846. https:\/\/doi.org\/10.1186\/s12913-021-06794-6","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"11135_CR85","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/liv.14334","volume":"40","author":"T Voulgaris","year":"2020","unstructured":"Voulgaris T, Papatheodoridi M, Lampertico P, Papatheodoridis GV. Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. Liver Int. 2020;40(3):484\u2013495. https:\/\/doi.org\/10.1111\/liv.14334","journal-title":"Liver Int"},{"key":"11135_CR86","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000317","author":"T Piratvisuth","year":"2023","unstructured":"Piratvisuth T, Hou J, Tanwandee T, Berg T, Vogel A, Trojan J, et al. Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies. Hepatol Commun. 2023. https:\/\/doi.org\/10.1097\/HC9.0000000000000317","journal-title":"Hepatol Commun"},{"issue":"11","key":"11135_CR87","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S2468-1253(22)00042-5","volume":"7","author":"E Jonas","year":"2022","unstructured":"Jonas E, Bernon M, Robertson B, Kassianides C, Keli E, Asare KO, et al. Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions. Lancet Gastroenterol Hepatol. 2022;7(11):1049\u20131060. https:\/\/doi.org\/10.1016\/S2468-1253(22)00042-5","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"11135_CR88","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/hep.28438","volume":"63","author":"G Papatheodoridis","year":"2016","unstructured":"Papatheodoridis G, Vlachogiannakos I, Cholongitas E, Wursthorn K, Thomadakis C, Touloumi G, et al. Discontinuation of oral antivirals in chronic hepatitis B: a systematic review. Hepatology. 2016;63(5):1481\u20131492. https:\/\/doi.org\/10.1002\/hep.28438","journal-title":"Hepatology"},{"issue":"1","key":"11135_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100617","volume":"5","author":"CH Tseng","year":"2023","unstructured":"Tseng CH, Chen TH, Wu JL, Lee TY, Borghi JA, Lin JT, et al. Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: a systematic review and meta-analysis. JHEP Rep. 2023;5(1): 100617. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100617","journal-title":"JHEP Rep"},{"issue":"Suppl 1","key":"11135_CR90","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/liv.13627","volume":"38","author":"S Marciano","year":"2018","unstructured":"Marciano S, Gadano A. Why not to stop antiviral treatment in patients with chronic hepatitis B. Liver Int. 2018;38(Suppl 1):97\u2013101. https:\/\/doi.org\/10.1111\/liv.13627","journal-title":"Liver Int"},{"issue":"1","key":"11135_CR91","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/hep4.1436","volume":"4","author":"AS Lok","year":"2020","unstructured":"Lok AS, Zoulim F, Dusheiko G, Chan HLY, Buti M, Ghany MG, et al. Durability of hepatitis B surface antigen loss with nucleotide analogue and peginterferon therapy in patients with chronic hepatitis B. Hepatol Commun. 2020;4(1):8\u201320. https:\/\/doi.org\/10.1002\/hep4.1436","journal-title":"Hepatol Commun"},{"issue":"5","key":"11135_CR92","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","volume":"67","author":"T Berg","year":"2017","unstructured":"Berg T, Simon KG, Mauss S, Schott E, Heyne R, Klass DM, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. J Hepatol. 2017;67(5):918\u2013924. https:\/\/doi.org\/10.1016\/j.jhep.2017.07.012","journal-title":"J Hepatol"},{"issue":"2","key":"11135_CR93","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/hep.29640","volume":"68","author":"WJ Jeng","year":"2018","unstructured":"Jeng WJ, Chen YC, Chien RN, Sheen IS, Liaw YF. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2018;68(2):425\u2013434. https:\/\/doi.org\/10.1002\/hep.29640","journal-title":"Hepatology"},{"issue":"8","key":"11135_CR94","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3851\/IMP3256","volume":"23","author":"GV Papatheodoridis","year":"2018","unstructured":"Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, et al. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. Antivir Ther. 2018;23(8):677\u2013685. https:\/\/doi.org\/10.3851\/IMP3256","journal-title":"Antivir Ther"},{"issue":"10","key":"11135_CR95","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/hep4.1708","volume":"5","author":"F van Bommel","year":"2021","unstructured":"van Bommel F, Berg T. Risks and benefits of discontinuation of nucleos(t)ide analogue treatment: a treatment concept for patients with HBeAg-negative chronic hepatitis B. Hepatol Commun. 2021;5(10):1632\u20131648. https:\/\/doi.org\/10.1002\/hep4.1708","journal-title":"Hepatol Commun"},{"issue":"2","key":"11135_CR96","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/hep.29497","volume":"68","author":"GV Papatheodoridis","year":"2018","unstructured":"Papatheodoridis GV, Manolakopoulos S, Su TH, Siakavellas S, Liu CJ, Kourikou A, et al. Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B. Hepatology. 2018;68(2):415\u2013424. https:\/\/doi.org\/10.1002\/hep.29497","journal-title":"Hepatology"},{"issue":"4","key":"11135_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jve.2024.100577","volume":"10","author":"N Posuwan","year":"2024","unstructured":"Posuwan N, Wasitthankasem R, Pimsing N, Phaengkha W, Ngamnimit S, Vichaiwattana P, et al. Hepatitis B prevalence in an endemic area of hepatitis C virus: a population-based study implicated in hepatitis elimination in Thailand. J Virus Erad. 2024;10(4): 100577. https:\/\/doi.org\/10.1016\/j.jve.2024.100577","journal-title":"J Virus Erad"},{"key":"11135_CR98","unstructured":"WHO. Global hepatitis report 2024: action for access in low- and middle-income countries, World Health Organization, Geneva. 2024:https:\/\/www.who.int\/publications\/i\/item\/9789240091672 (accessed date: 27 Mar 2026)"},{"issue":"6","key":"11135_CR99","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S2468-1253(24)00089-X","volume":"9","author":"PJ Easterbrook","year":"2024","unstructured":"Easterbrook PJ, Luhmann N, Bajis S, Min MS, Newman M, Lesi O, et al. WHO 2024 hepatitis B guidelines: an opportunity to transform care. Lancet Gastroenterol Hepatol. 2024;9(6):493\u2013495. https:\/\/doi.org\/10.1016\/S2468-1253(24)00089-X","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"11135_CR100","doi-asserted-by":"publisher","DOI":"10.54394\/CJQU6666","volume-title":"Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries. Geneva: WHO; 2024"},{"issue":"4","key":"11135_CR101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001624","volume":"11","author":"AG Singal","year":"2014","unstructured":"Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11(4): e1001624. https:\/\/doi.org\/10.1371\/journal.pmed.1001624","journal-title":"PLoS Med"},{"key":"11135_CR102","unstructured":"Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022\u20132030. Geneva: WHO 2022; https:\/\/www.who.int\/publications\/i\/item\/9789240053779"},{"key":"11135_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101129","volume":"48","author":"A Lee","year":"2024","unstructured":"Lee A, Hilmers D, Russell T. A new hepatitis B elimination strategy for remote populations is needed. Lancet Reg Health West Pac. 2024;48: 101129. https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101129","journal-title":"Lancet Reg Health West Pac"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11135-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11135-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11135-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:16:51Z","timestamp":1785770211000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-026-11135-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":103,"alternative-id":["11135"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11135-y","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tawesak Tanwandee has received research grants from Bristol Myers Squibb and Merck. Teerha Piratvisuth has received research grants from Gilead Sciences, Roche Diagnostics, Janssen, Fibrogen, and VIR, and honoraria from Bristol Myers Squibb, Gilead Sciences, Bayer, Abbott, Eisai, Mylan, Ferring, and MSD. Phunchai Charatcharoenwitthaya, Pisit Tangkijvanich, Chatree Jullapetch, Cheewanan Lertpiriyasuwat, and Pongtorn Chartpitak declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The development of this guideline was conducted with full transparency and adherence to international standards for clinical practice guidelines.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}